Shots:

• The approval is based on two P-III studies assessing the combination of dapagliflozin (5mg- 10mg) -saxagliptin (5mg) and metformin in patients with inadequately controlled Type-2 diabetes for 24wks.
• The collective studies result demonstrated a reduction in HbA1c (average blood glucose levels) & increment in no. pf patients achieving HbA1c <7%
• Qternmet XR (qd- PO) is a triple combination therapy consisting of dapagliflozin (sodium‑glucose cotransporter-2 (SGLT-2) inhibitor)- saxagliptin (dipeptidyl peptidase‑4 (DPP‑4) inhibitor) & metformin hydrochloride - approved by FDA as an adjunct to diet and exercise for improving glycaemic control in adults with T-2D

Ref: AstraZeneca | Image: AstraZeneca